Contributor Disclosures for Toxicity, Monoamine Oxidase Inhibitor

Role Name Disclosure Details Author  Soumya Ganapathy, MD, Consulting Staff, Department of Emergency Medicine, Union Memorial Hospital Nothing to disclose Details Coauthor  Frank A Maffei, MD, FAAP, Associate Professor of Pediatrics, Temple University School of Medicine; Director of Medical Student Affairs, Geisinger Health System; Pediatric Critical Care Attending Physician, Janet Weis Children's Hospital at Geisinger Medical Center Nothing to disclose Details Medical Editor  Michael E Mullins, MD, Assistant Professor, Department of Emergency Medicine, Washington University School of Medicine Nothing to disclose Details Pharmacy Editor  Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine.com, Inc Pfizer Inc Avanir Pharma Details Managing Editor  Jeffrey R Tucker, MD, Assistant Professor, Department of Pediatrics, Division of Emergency Medicine, University of Connecticut and Connecticut Children's Medical Center Nothing to disclose Details CME Editor  Paul D Petry, DO, FACOP, FAAP, Clinical Assistant Professor of Pediatrics, University of North Dakota, School of Medicine and Health Sciences; Consulting Staff, Altru Health System Nothing to disclose Details Chief Editor  Timothy E Corden, MD, Associate Professor of Pediatrics, Co-Director, Policy Core, Injury Research Center, Medical College of Wisconsin; Associate Director, PICU, Children's Hospital of Wisconsin Nothing to disclose Details CONTRIBUTOR DISCLOSURE FORM Contributor Name: Soumya Ganapathy  DECLARATION STATEMENT I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. COMMERCIAL INTEREST (Name of Organization) Self Spouse/ Partner NATURE OF RELEVANT FINANCIAL RELATIONSHIP What was received?* For what role?** Off label or investigational use of medication Contributor Disclosure Contributor: Contributor Disclosure: Frank A Maffei, Coauthor  The contributor discloses no conflict of interest.  Contributor Disclosure Contributor: Contributor Disclosure: Michael E Mullins, Medical Editor  The contributor discloses no conflict of interest.  CONTRIBUTOR DISCLOSURE FORM Contributor Name: Mary L Windle  DECLARATION STATEMENT I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. COMMERCIAL INTEREST (Name of Organization) Self Spouse/ Partner NATURE OF RELEVANT FINANCIAL RELATIONSHIP What was received?* For what role?** Pfizer Inc Stock Investment from broker recommendation   Avanir Pharma Stock Investment from broker recommendation   Off label or investigational use of medication Contributor Disclosure Contributor: Contributor Disclosure: Jeffrey R Tucker, Managing Editor  The contributor discloses no conflict of interest.  Contributor Disclosure Contributor: Contributor Disclosure: Paul D Petry, CME Editor  The contributor discloses no conflict of interest.  CONTRIBUTOR DISCLOSURE FORM Contributor Name: Timothy E Corden  DECLARATION STATEMENT I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. COMMERCIAL INTEREST (Name of Organization) Self Spouse/ Partner NATURE OF RELEVANT FINANCIAL RELATIONSHIP What was received?* For what role?** Off label or investigational use of medication